Cardiac Biomarkers Market Size

Cardiac Biomarkers Market Future Prospects

The global cardiac biomarkers market size is USD 20.8 billion in 2024, and it is expected to generate USD 44.6 billion by 2030, advancing with a robust CAGR of 13.4% during 2025-2030.

The market is driven by the growing rate of acute coronary syndromes (ACS), which are an ongoing challenge for healthcare systems across the world. The technological advancements in cardiac biomarkers, such as high-sensitivity troponin assays, have made early detection and risk stratification easier and reduced diagnostic uncertainties.

Further, the ever-growing usage of point-of-care (POC) testing kits enables faster clinical decision-making in emergency cases, thereby improving patient outcomes. The need for higher specificity and sensitivity in detecting cardiac conditions, especially myocardial infarctions, drives the demand for new biomarker solutions.

The investments put in by government and private institutions in research and development in this area of diagnostics encourage product innovations. The geriatric population is more vulnerable to heart diseases; thus, the demand for sophisticated diagnostic solutions is high. The rising awareness among healthcare professionals and patients of early diagnosis further boosts the growth of the market.